Bausch + Lomb

Treating inflammation tackles filamentary keratitis
Treating inflammation tackles filamentary keratitisCorneal filaments frequently recur after removal, and resolution occurs only by treating the patient’s underlying inflammation. This case illustrates the need to move to atypical therapies, such as N-acetylcysteine.
‘Hypersonic’ vitrectomy overcomes flaws of traditional systemsUsing ultrasonic power to actuate a vitrectomy probe (hypersonic vitrectomy) allows for a “smooth steady flow of vitreous into a port that is oscillating at 1.7 million cycles per minute,” according to Carl C. Awh, MD.
Every New FDA Drug Approval in 2017
Every New FDA Drug Approval in 2017The last 12 drugs approved in the year, along with the other 34.
New glaucoma therapy offers first drug option in years
Using OCTA in optometric practice
Using OCTA in optometric practiceBy using OCTA technology, we are able to take better care of our patients with retinal disease, make smarter referrals, or be able to hold on to our patients, knowing a referral is not needed.
Understanding the conundrum of conjunctivochalasisConjunctival chalasis, or conjunctivochalasis (Cch), is a commonly observed condition in our everyday patient care experiences. Because it is so common, and because a majority of patients are asymptomatic, optometrists seldom feel the need treat.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
B+L next-generation surgical platform features advanced retina capabilities
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.